CardiaTech Solutions Secures $6.5 Million in Seed Funding to Propel eClinical Solutions Platform

In an exciting development for the biopharma research community, CardiaTech Solutions has successfully secured $6.5 million in funding, aimed at enhancing its innovative data and analytics platform, elluminate®. As a key player in the life sciences sector, eClinical Solutions leverages cutting-edge technology and expert biometrics services to streamline clinical trials for organizations of all sizes, from large pharmaceutical companies to emerging biotech firms. This funding will be instrumental in advancing our mission to reduce trial complexity and increase efficiency, allowing our clients to deliver timely and accurate insights for better decision-making. The investment will not only support the enhancement of our platform but also expand our capabilities in delivering unparalleled resources and support to our clients, ultimately helping them to accelerate breakthrough therapies. As a privately-held, purpose-driven company, eClinical Solutions takes pride in its recognition as one of the Top Workplaces USA and recipients of the Culture Excellence Awards 2024, as well as the Great Place To Work® India Certification™. With a dedicated global workforce at the helm, we are poised to utilize this funding to further enhance our solutions and continue to foster a culture of excellence and innovation. Visit eclinicalsol.com to learn more about how we are shaping the future of biopharma research through our industry-leading technology and services.